Lasofoxifene + abemaciclib shows potential in ER+/HER2− breast cancer with ESR1 mutation

COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

COTA, a leader in real-world data and analytics for oncology, is entering a collaboration with Sanofi to use RWD and artificial intelligence to increase the speed of oncology trials, including for multiple myeloma.

April 19, 2024

Vol.50 No.16

Clinical Roundup

Radiation before mastectomy cuts time delays for reconstructive surgery in breast cancer patients

Researchers at MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays, and improved patient satisfaction.

April 12, 2024

Vol.50 No.15

In Brief

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

Antonio C. Wolff, chair of the Breast Cancer Committee for the ECOG-ACRIN Cancer Research Group, will co-lead the Breast Cancer Steering Committee for NCI. He began the three-year term on April 1.

April 05, 2024

Vol.50 No.14

Clinical Roundup

One in five people with cancer participate in medical research studies, Fred Hutchinson study shows

Researchers from Fred Hutchinson Cancer Center, the American Cancer Society Cancer Action Network, and peer institutions released findings in the Journal of Clinical Oncology showing that when all types of cancer research studies are considered, at least one in five people with cancer, or 21.9%, participate in some form of clinical research.

April 05, 2024

Vol.50 No.14

Clinical Roundup

Study finds TNBC tumors with an increase in immune cells have lower risk of recurrence after surgery

A multicenter, international study suggests that people who have early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes within their tumors may have a lower risk of recurrence and better survival rates, even when not treated with chemotherapy.

April 05, 2024

Vol.50 No.14

Regulatory News

Exercising new powers, FDA issues Complete Response Letters based on insufficient enrollment in confirmatory trials

FDA issued Complete Response Letters for the Biologics License Application for odronextamab in relapsed/refractory follicular lymphoma and in R/R diffuse large B-cell lymphoma, each after two or more lines of systemic therapy.

March 29, 2024

Vol.50 No.13

By Paul Goldberg

Lasofoxifene + abemaciclib shows potential in ER+/HER2− breast cancer with ESR1 mutation

YOU MAY BE INTERESTED IN

COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI

Radiation before mastectomy cuts time delays for reconstructive surgery in breast cancer patients

Antonio Wolff named co-lead of NCI Breast Cancer Steering Committee

One in five people with cancer participate in medical research studies, Fred Hutchinson study shows

Study finds TNBC tumors with an increase in immune cells have lower risk of recurrence after surgery

Exercising new powers, FDA issues Complete Response Letters based on insufficient enrollment in confirmatory trials

Renew today!

Subscriber content

Login